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Abstract 
The field of RNA therapeutics is currently undergoing both transformation and 
expansion. Specifically, research in lipid nanoparticle (LNP) based RNA therapeutics is 
gaining significant traction. Other research into mechanisms of gene regulation and 
manipulation, including siRNA and the CRISPR/Cas9 system have demonstrated the 
potential of RNA-based disease treatment. This work identifies a delivery system which 
can regulate expression of green fluorescent protein (GFP) in human embryonic kidney 
cells (HEK293) stably expressing GFP.  
Analysis of siRNA-induced gene knockdown demonstrates that the current siRNA-
LNP formulation is equally as effective as a commercially available transfection reagent, 
Lipofectamine RNAiMAX (RNAiMAX), which is designed specifically for plate-based 
transfection experiments. The siRNA-LNP formulation can reduce GFP expression to 
30% with cytotoxicity slightly lower than RNAiMAX. CRISPR formulations also resulted in 
significant knockdown, though further research is needed to optimize and verify loss of 
GFP expression. 
Particle characterization of both siRNA-LNP and CRISPR RNA-LNP formulations 
reveals that particles of low size (~100 nm) and low polydispersity index (PDI < 0.10) can 
be achieved, demonstrating their in vivo applicability and potential for further 
pharmaceutical development. 
This study also outlines a route for continued formulation development through 
evaluation of a complex processing stream. An RNase detection assay reveals that RNA-
LNPs can be produced using a continuous processing system without risk of degradation. 
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Introduction 
Implications and significance 
RNA therapeutics are a rapidly growing field of pharmaceutics that 
have enormous potential for the treatment of hereditary genetic diseases and various 
cancers. In the United States alone, close to 1,800,000 new cancer cases are expected 
by the end of 2019 and over 600,000 are predicted to lose their battle by the end of 2019 
(Siegel, Miller, & Jemal, 2018).  Both siRNA and the CRISPR/Cas9 system have been 
successfully used in vivo to inhibit the expression of genes and for gene knockout, 
respectively, with the end  goal of treating genetic disease and the genetic underpinnings 
of cancer (Mout, Ray, Lee, Scaletti, & Rotello, 2017; Shim & Kwon, 2010) . However, 
developing viable therapeutics for clinical use remains a challenge due to 
complications in systemic delivery (Kaczmarek, Kowalski, & Anderson, 2017). To date, 
there is a lack of robust and significant formulation development work for CRISPR/Cas9 
delivery. Accordingly, my project sought to develop novel strategies for the delivery of two 
gene therapeutics. To complete this study: (i) an siRNA delivery vehicle was developed 
by utilizing lipid nanoparticles, (ii) a novel delivery vehicle for the CRISPR/Cas9 gene 
editing system was developed, and (iii) HEK-293 were transfected to investigate the 
efficacy and cytotoxicity of the developed formulations. This project provides valuable 
information on the development of systemic RNA therapeutics and helps bridge the gap 
between basic science and its translation to medicine. 
Core features of siRNA 
RNA interference is a basic biological process that allows cells to regulate their 
gene expression patterns through precise manipulation and targeting of endogenous 
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mRNA molecules (Hannon, 2002) . In this endogenous pathway, double-stranded RNA 
(dsRNA) is cleaved by the enzyme Dicer to form ~21 nucleotide fragments of siRNA in 
duplex form.  
 
 
siRNA
RISC
RISC incorporation
mRNA degradation
mRNA
Dicer processing
Passenger strand
Guide strand
Figure 1. Schematic of core features of siRNA-induced gene silencing. An siRNA 
molecule (gray strand and red strand) is delivered into a cell, processed by Dicer, and 
incorporated into RISC (yellow oval). The siRNA molecule binds to its complimentary 
mRNA sequence (green strand) and the cleavage is catalyzed. The RISC, though 
represented by a yellow oval, is a complex of multiple proteins including Argonaut. 
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One strand, referred to as the passenger strand, is discarded while the other, 
referred to as the guide strand, is incorporated into an argonaute, a critical component of 
the RNA-induced silencing complex (RISC) (Carthew & Sontheimer, 2009). The 
argonaute plays an important role in guiding the RNA strand to its complimentary mRNA 
and in catalyzing the cleavage and subsequent degradation of the mRNA (Carthew & 
Sontheimer, 2009). The pathway for synthetic siRNA is very similar to the endogenous 
pathway. Once siRNA enters a cell, it is processed by Dicer and its guide strand is 
incorporated into RISC (Figure 1). 
The core features of this pathway can be utilized to treat a variety of diseases, 
particularly ones which may be associated with the expression or over-expression of an 
undesirable gene. Specifically, the possibility of targeting oncogenes opens assessment 
of siRNA as a potential chemotherapeutic. Targeting cancer associated genes such as c-
raf and bcl-2 has shown promise in myeloid leukemia cell lines  (Cioca, Aoki, & Kiyosawa, 
2003) and many other prospects have been established (Pai et al., 2005). More recent 
developments have successfully targeted other disease-related genes. In 2018, an RNAi 
therapeutic Patisiran for Hereditary Transthyretin Amyloidosis developed by Alnylam 
Pharmaceuticals passed phase III clinic trials  (Adams et al.,2018). Continued formulation 
work is required to expand the possible repertoire of targetable genes. 
Core features of the CRISPR/Cas9 system 
Originally discovered as a defense mechanism in bacteria and archaea, 
CRISPR/Cas technology has revolutionized the field of basic biology research. Clustered 
regularly interspaced short palindromic repeats (CRISPR) and their associated 
components provide adaptive immunity against viruses and foreign plasmids. At the core 
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of this mechanism, CRISPR RNAs (crRNAs) are base-paired to trans-activating crRNAs 
(tracrRNAs). This crRNA:tracrRNA complex (gRNA) guides CRISPR-associated protein 
9 (Cas9) to complimentary DNA, catalyzing double-stranded breaks in DNA upstream of 
a protospacer-adjacent motif (PAM) sequence (Jinek et al., 2012). This system has been 
engineered to function in eukaryotic cells, inducing double-stranded breaks within the 
genome (Cong et al., 2013). After the double-stranded breaks are generated within the 
Figure 2. Schematic of core features of CRISPR-Cas9 induced gene knockout.  
gRNA and Cas9 mRNA have been delivered into the cell. Cas9 mRNA undergoes 
translation in the cytoplasm to generate a Cas9 protein which then associates with the 
gRNA. The gRNA guides the Cas9/gRNA complex to its complementary strand of 
genomic DNA. After association, Cas9 catalyzes double stranded breaks in the genome, 
and the cell proceeds to NHEJ or HDR. 
gRNA
Cas9 
mRNA
TranslationIncorporation
Cas9/gRNA 
complex
Genomic DNA
Cas9/gRNA 
complex
Double-stranded 
break
crRNA
tracrRNA
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genome, the cell’s machinery initiates one of two repair pathways: (1) In the non-
homologous end joining (NHEJ) pathway, DNA is repaired by introducing insertion-
deletion (indel) mutations; (2) In the homology-directed repair pathway, cells repair the 
DNA by utilizing a DNA template. Indel mutations generated by NHEJ can produce non-
functional genes and are the cornerstone of CRISPR knock-out experiments.  
By incorporating Cas9 plasmids into cell lines or different animal models, it is 
possible to target specific genes for functional analysis through delivery of gRNA by viral 
transfection, lipid transfection, electroporation, or micro-injection. Delivery of this 
synthetic gRNA has opened the door for more significant pharmaceutical developments. 
Instead of dosing treatments for extended periods of time, diseases can be cured by 
permanently knocking out a disease-related gene. The schematic shown in Figure 2 
provides information on the mechanism utilized by the CRISPR/Cas9 system to induce 
the permanent changes. 
Lipid nanoparticle (LNP) formation 
A variety of nanoparticles have been developed over the years for use in drug 
delivery, disease diagnostics, and materials science (Patra et al., 2018) . These particles 
include but are not limited to liposomes, LNPs, polymeric micelles, and quantum dots 
(Patra et al., 2018). For drug delivery purposes, LNPs can be used to encapsulate a drug 
within a solid core composed of a variety of lipids (Schubert & Müller-Goymann, 2003). 
LNPs can be produced using a number of different techniques. For ease of use and 
reproducibility, the solvent-injection method was chosen to produce LNPs (Schubert & 
Müller-Goymann, 2003). The basic principle of this technique relies on hydrophobic and 
electrostatic interactions between solutes dissolved in two miscible solvents. In general, 
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lipids are dissolved in ethanol, a water-miscible organic solvent. They are then rapidly 
mixed with water or an aqueous buffer, promoting hydrophobic interactions between the 
non-polar hydrocarbon tails of the lipids and hydrogen bond formation between the 
hydrophilic heads of the lipids and the surrounding water. Solid lipid nanoparticles are 
formed when the inner core of the LNP is composed of a matrix of lipid. As an example, 
charged lipid that interacts with RNA may form a solid structure, that is then surrounded 
by other lipid molecules, forming a particle that protects the RNA from nuclease 
degradation. In order to produce RNA-loaded LNPs, RNA can be dissolved into an 
aqueous buffer and rapidly mixed with lipid solutions. During this process, interaction 
between hydrophilic components of the lipids supports encapsulation of the RNA. 
Electrostatic interactions between the negatively charged phosphate backbone of RNA 
and the positively charged components of cationic or zwitterionic lipids can also promote 
encapsulation. Controlled microfluidic techniques allow for tight regulation of LNP particle 
size, resulting in a high-quality formulation. 
Materials 
Lipids 
The lipids used in the formulations were purchased from Avanti Polar Lipids. 
Coatsome® SS-OC was purchased from NOF America. Lipofectamine RNAiMAX and 
Lipofectamine MessengerMAX from Invitrogen were used as positive control transfection 
reagents. 
In order to avoid the significant toxicity and maintain the transfection efficacy of 
cationic lipids (Lv, Zhang, Wang, Cui, & Yan, 2006), multiple lipid types were utilized. The 
lipids used in this study were combinations of neutral, zwitterionic, anionic, and cationic 
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lipids. As a neutral lipid, cholesterol (Figure 5A) is commonly found in the lipid bilayer of 
living cells, maintaining both their fluidity and rigidity. DOPE (Figure 4B) is a zwitterionic 
lipid with a positive charge contributed from its amine group and a negative charge 
contributed from its phosphate group. It is known as a “helper lipid” which promotes 
membrane fusion by producing inverted hexagonal lipid structures (Du, Munye, 
Tagalakis, Manunta, & Hart, 2014) DC-Cholesterol (Figure 5C) is a cationic lipid with a 
positively charged amine group whose main-body structure is identical to cholesterol. 
DSPE-mPEG2000 (Figure 5D) is an anionic lipid whose charge originates from its 
phosphate group.  Coatsome® SS-OC is a neutral lipid with two identical monomers 
linked by a disulfide bond. This cleavable disulfide bond is disrupted in reducing 
environments such as the cytoplasm or in the endosome. The endosome can be defined 
as a compartment which forms when cells engulf LNPs  (Wittrup et al., 2015). In 
appropriate ratios and under the rapid-mixing conditions, these lipids form particles which 
are capable of encapsulating RNA and targeting GFP in HEK293 cells. 
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B. DOPE
C.
DC-Cholesterol
D. DSPE-mPEG2000
E. Coatsome© SS-OC
A. Cholesterol
 
Figure 3. Structures of lipids utilized in this study. (A) cholesterol. (B) 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE), a zwitterionic lipid. (C) 3b[N-(N’,N’-
dimethylaminoethane)-carbamoyl]cholesterol hydrochloride (DC-Cholesterol). (D) 1,2-
diastearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000 
and (E) Coatsome® SS-OC. Structures were provided by the vendors.  
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RNA Sequences 
siRNA duplex targeting GFP of the sequence 5’ GCACCAUCUUCUUCAAGGA 3’ 
was provided by the MIT/ICBP siRNA Database and purchased from Millipore Sigma with 
[dT][dT] overhangs on both sense and antisense strands. crRNA with the target sequence 
5’ GCACGGGCAGCTTGCCGG 3’ and Readymade tracrRNA were purchased from IDT. 
The crRNA target sequence was provided by an Applied Biological Materials protocol 
involving a CRISPR knockout experiment using a viral Cas9 plasmid.  
Cell Culture and Assay Materials 
A GFP expressing HEK-293 stable cell line was purchased from Applied Biological 
Materials. Black 96-well BD-Falcon plates with clear bottoms were used for GFP and cell 
viability assays fluorescent assays along with a Tecan Safire2 fluorescent plate reader 
and Magellan software. A Qubit microRNA kit was used with the Qubit 4 Fluorometer to 
obtain RNA concentrations for encapsulation assays. GFP was measured at and 
excitation wavelength of 490 nm and an emission wavelength of 510 nm. Cell viability 
assays were performed with the CellTiter-Blue® reagent from Promega according to the 
manufacturer’s protocol at an excitation wavelength of 560 nm and an emission 
wavelength of 590 nm. Samples were run at n=6 for each transfection experiment. 
Methods 
LNPs were formed and assays were performed following a series of steps which 
are outlined in Figure 3. Two syringe pumps injected lipid and RNA solutions into a T-
tube micromixer. The particles were then collected for cell transfection, Zetasizer assays 
(particle size and PDI), RNA encapsulation efficiency assays, and for cell transfection. 
The efficacy of RNA-LNP formulations was evaluated based upon their ability to decrease 
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GFP expression in HEK-293 cells stably expressing GFP. After transfection, GFP 
fluorescence was measured periodically and cell viability was measured at the end. 
Schematics depicted in this study were created using Microsoft PowerPoint and tables 
were created using Microsoft Excel. Graphs describing changes in fluorescence and 
particle size were generated using Prism 8. 
 
 
Figure 4. Schematic of Experimental Workflow. Two syringe pumps control the flow 
of nucleic acids and lipid into a T-tube micromixer, promoting formation of RNA-loaded 
LNPs. The LNPs are then prepared for dynamic light scattering assays and RNA 
encapsulation efficiency assays. Once cells are transfected, GFP fluorescence and cell 
viability assays are performed.  
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siRNA LNP and CRISPR LNP synthesis 
All LNP formulations were produced using the T-tube micromixer shown in Figure 
4. The intersection of this T-tube micromixer is the location of turbulent flow, which 
enables rapid mixing of the different components, in this case lipid and RNA. The flow of 
lipid and nucleic acid solutions is independently controlled by a LabVIEW GUI on a 
computer not shown in this figure. 
 
 
Powdered lipid purchased from vendors described in the materials section was 
weighed and mixed into ethanol. The solution was then briefly heated and sonicated to 
promote solvation of the lipid at concentrations ranging from 4.7 mM to 15 mM. RNA was 
dissolved in RNase free water at high concentrations (~10 mg/mL) and was added to 0.01 
M citrate buffer (pH 3.96) to achieve a final concentration of 0.05 mg/mL for siRNA and 
gRNA formulations and 0.005 mg/mL for formulations containing mRNA. Prior to diluting 
LNPs
Nucleic 
acid (aq)Lipid (o) T-tube micromixer
Figure 5. Layout of T-tube micromixer. Two syringe pumps control the flow of nucleic 
acids and lipid into T-tube micromixer shown on the left, which was used to produce 
LNPs. A cartoon diagram to the right shows the flow of nucleic acid dissolved in buffer 
(Nucleic acid (o) injected into a T-tube along with lipid dissolved in ethanol (Lipid (o)). 
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with citrate buffer, crRNA and tracrRNA were mixed at a molar ratio of 1:1, placed in an 
80 ºC water bath for 5 min, then cooled on the benchtop to allow annealing. Lipid and 
RNA solutions were then loaded into syringes to be injected into the T-tube micromixer. 
A Valco T-tube micromixer with a 0.006” diameter bore was connected to two Harvard 
Apparatus Pico Plus Elite OEM syringe pumps controlled by the LabVIEW software. 
HPLC tubing (ID of 0.007” ) connected the syringes via leur lock fittings. Flow rates were 
adjusted using LabVIEW to obtain optimal mixing conditions and ranged from 400 uL/min 
to 6000 uL/min. The flow rates, percentages of total flow, and lipid concentrations used 
for each formulation are listed in Table 1 for siRNA formulations and in Table 2 for 
CRISPR formulations.  
 
The molar quantities of the lipids used to produce the formulations are described 
in Table 3. siRNA:LNP_2-PEG and siRNA:LNP-SS-OC-PEG were produced by adding 
Formulation name flow (uL/min) %flow
[Lipid] 
(mM) flow (uL/min)
siRNA:LNP 400 17 4.7 1953
siRNA:PEG-LNP 400 9.1 10 4000
siRNA:LNP_2 400 9.1 10 4000
siRNA:LNP-SS-OC 400 9.1 10 4000
siRNA:LNP_2-PEG 400 9.1 10 4000
siRNA:LNP-SS-OC-PEG 400 9.1 10 4000
siRNA:LNP-SS-OC_2 400 6.3 15 6000
%flow
90.9
90.9
90.9
93.8
Ethanol & Lipid Phase Flow Aqueous Phase Flow 
83
90.9
90.9
Table 1. Flow conditions for siRNA-loaded LNP production. 
 
 
Table 2. Flow conditions for CRISPR gRNA and mRNA-loaded LNP production. 
 
 
Formulation name flow (uL/min) %flow
[Lipid] 
(mM) flow (uL/min)
gRNA:LNP 400 6.3 15.0 6000
mRNA:LNP 400 9.1 1.0 4000
gRNA:mRNA:LNP 400 9.1 1.0 4000
Ethanol & Lipid Phase Flow Aqueous Phase Flow 
90.9
90.9
%flow
93.8
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PEG lipid with a pipette after formation of the particles so that the PEG was at 5% mole 
ratio of the total lipid. As shown in Table 3, these were post-formation, or PF. Flow 
conditions were adjusted to produce the particles characterized in the particle sizing, 
encapsulation, and transfection assays described below.  
  
In general, flow rates were adjusted empirically to obtain formulations with no 
noticeable turbidity. Formulations that produced turbid LNP complexes were not 
characterized by DLS, encapsulation efficiency assays or used in transfection 
experiments. 
Particle size Analysis 
Particle size analysis was performed using dynamic light scattering (DLS). After 
producing the LNP samples with the T-tube micromixer, the concentration of ethanol 
varied based upon the flow rates described in Table 1 and Table 2. In order to ensure 
particle sizing was consistent among different formulations, samples were diluted with 
0.01 M citrate buffer to 5 % ethanol to prepare for sizing analysis. One milliliter of each 
sample was loaded in a plastic cuvette and tested for Z-Average size (particle size) and 
polydispersity index (PDI) using a Malvern Zetasizer Nano ZSP. Measurement 
DOPE DC-Cholesterol Cholesterol SS-OC DSPE-mPEG2000
siRNA:LNP 15.0 28.3 56.6 N/A N/A
siRNA:LNP_2 15.0 28.3 56.6 N/A N/A
siRNA:LNP-SS-OC 15.4 23.5 58.4 2.7 N/A
siRNA:PEG_2-PEG 14.7 27.7 55.4 N/A PF
siRNA:LNP-SS-OC-PEG 15.4 23.5 58.4 2.7 PF
siRNA:LNP-SS-OC_2 15.4 23.5 58.4 2.7 N/A
gRNA:LNP 15.0 28.3 56.6 N/A N/A
mRNA:LNP 15.0 28.3 56.6 N/A N/A
gRNA:mRNA:LNP 15.0 28.3 56.6 N/A N/A
Lipid Component (mol%)
Formulation Name
Table 3. Mol % of lipids within each formulation produced. PF indicates PEG lipid 
that was added post-formation of LNPs. 
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parameters such as laser position and attenuation were set to automatic. Measurements 
were run in triplicate. 
Encapsulation Efficiency Analysis 
To calculate the encapsulation efficiency of a sample, LNPs were lysed using 
detergent to release RNA. Each formulation was divided into two samples. One sample 
was diluted 1:20 in RNase free water and the other was diluted 1:20 with Triton X-100 
(TX-100) to reach a final concentration of 0.05% TX-100. The encapsulation efficiency 
was taken to be a percent calculated by: 
 [RNA]entrapped = ([RNA]TX – [RNA]water)/ [RNA]TX Eq. 1 
 % RNAentrapped = ([RNA]TX – [RNA]water)/ [RNA]TX * 100% Eq. 2 
The RNA concentration was determined using the Qubit 4 (Invitrogen) fluorometer and 
the microRNA assay kit according to the manufacturer’s protocol. 
Transfection and Fluorescence Transformation 
HEK293 cells stably expressing GFP were grown in T-75 or T-25 flasks prior to 
plating for transfection. Growth media consisted of DMEM (no phenol red), 10% fetal 
bovine serum (FBS), 1X penicillin and or streptomycin, and 0.6 µg/mL puromycin. Cells 
were grown at 37 ºC and 5 % CO2 and passaged at 70-80 % confluency. The day before 
transfection, cells were counted using a TC-10™ Automated Cell Counter and plated at 
a density of 10,000 cells/well in a 96 well format at n = 6 for each condition. siRNA LNPs 
were added to the wells at 50 ng/well. gRNA was added at a concentration of 2.5 ng/well 
and mRNA was added at a concentration of 25 ng/well. RNA was diluted with optiMEM 
serum-free media to ensure the total volume added to each well was 20 µL. The 
transformation performed to normalize GFP fluorescence to cell viability was: 
 18 
 (GFPsample/CVsample) / (GFPcontrol/CVcontrol) * 100% Eq. 3 
While the transformation to independently monitor cell viability was: 
 (CVsample) / (CVcontrol) * 100% Eq. 4 
In this transformation, GFP is the fluorescence of GFP and CV is the fluorescence from 
the cell viability assay. Control refers to samples in which only OptiMEM was added. One-
way ANOVA was performed with Prism 8 to determine the significance of GFP 
knockdown between transfected samples and the OptiMEM control. 
RNase Detection Assay 
RNase contamination was assayed by collecting samples of water before and after 
thorough cleaning of the continuous processing system and tangential flow filtration (TFF) 
apparatus. RNaseZAP® was rinsed through the system. Ethanol was then briefly flushed 
through followed by several gallons of water. RNaseAlert™ was purchased from IDT and 
used according to the manufacturer’s protocol to detect RNases. Incubation steps were 
conducted for one hour (Du et al., 2014). 
Results 
siRNA Formulations 
After transfection, significant knockdown was seen for multiple siRNA 
formulations. Different formulations were characterized by their particle size and PDI, as 
well by their ability to knockdown GFP expression. As shown in Figure 6, Significant GFP 
knockdown (p < 0.0001) was observed with siRNA-loaded LNPs (siRNA:LNP) as well as 
with the positive control commercial transfection reagent, Lipofectamine RNAiMAX 
(siRNA:RNAiMAX).  
 19 
  
Figure 6. siRNA Run 1 formulation summary. PEGylated and non-PEGylated LNPs 
were formulated in order to deliver siRNA. Cell viability (A) was assayed after 96 hours 
along with GFP expression (B). PDI (C) and particle size (D) of the particles was also 
evaluated. GFP fluorescence was measured over time (E). The dashed line in B indicates 
a PDI of 0.1. **** p < 0.0001. 
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Normalized GFP expression for siRNA:LNP was 33.21 ± 4.84 % of the control and 
36.9 ± 6.95 % for siRNA:RNAiMAX, though the difference between the two samples was 
not significant. PEGylated LNPs (siRNA:PEG-LNP) did not register any significant 
knockdown. siRNA:LNP resulted in saw no loss in viability while siRNA:RNAiMAX saw a 
13 % loss in cell viability when compared to the OptiMEM control. Under the conditions 
provided in the methods section, the siRNA:LNP formulation produced particles 302 ± 6.8 
nm in diameter with a PDI of 0.13 ± 0.05. The siRNA:PEG-LNP formulation produced 
particles that were 120.93 ± 1.65 nm in diameter with a PDI of 0.09 ± 0.01. The dashed 
lines present in Figure 6C indicate a PDI of 0.1, a loose cut-off to describe formulations 
which are monodispersed.  
In order to evaluate the possibility of producing additional formulations capable of 
knocking down GFP, more were produced with different lipids under varying flow 
conditions outlined in the methods portion in Tables 1, 2, and 3. The results from particle 
size analysis and cell culture assays are presented in Figure 7. 
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Significant GFP knockdown was noticed for siRNA:LNP, siRNA:LNP_2, 
siRNA:LNP-SS-OC, and siRNA:LNP-SS-OC_2 formulations and for the siRNA:RNAiMAX 
positive control. Normalized GFP fluorescence for those samples was 54.58 ± 6.51 %, 
61.69 ± 8.13 %, 60.84 ± 8.34 %, 60.78 ± 6.60 %, and 35.79 ± 5.00 %, respectively. No 
significant loss in cell viability was noticed for any of the samples. After determining the 
efficacy of these formulations, they were adopted to produce LNPs with CRISPR gRNA 
and CRISPR mRNA. Particle sizes and PDI for siRNA:LNP, siRNA:LNP_2, siRNA:LNP-
SS-OC, and siRNA:LNP-SS-OC_2 were 547.27 ± 18.62 nm and 0.30 ± 0.04, 179.4 ± 0.9 
Figure 7. siRNA Run 2 formulation summary. LNPs were formulated in order to deliver 
siRNA. Cell viability (A) was assayed after 96 hours along with GFP expression (B). PDI 
(C) and particle size (D) of the particles were also evaluated. **** p < 0.0001.  
 
80
100
120
N
or
m
al
iz
ed
 V
ia
bi
lit
y 
%
A.
siR
NA
:LN
P
siR
NA
:LN
P_
2
siR
NA
:LN
P-
SS
-O
C
siR
NA
:LN
P_
2-P
EG
siR
NA
:LN
P-
SS
-O
C-
PE
G
siR
NA
:LN
P-
SS
-O
C_
2
siR
NA
:R
NA
iM
AX
Op
tiM
EM
0
50
100
N
or
m
al
iz
ed
 F
lu
or
es
ce
nc
e 
% B.
**** **** **** ****
****
0.0
0.1
0.2
0.3
0.4
PD
I
C.
siR
NA
:LN
P
siR
NA
:LN
P_
2
siR
NA
:LN
P-
SS
-O
C
siR
NA
:LN
P-
SS
-O
C_
2
0
200
400
600
Pa
rit
cl
e 
si
ze
 (n
m
)
D.
siRNA Run 2 Formulation Characterization and Efficacy
 22 
nm and 0.09 ± 0.02, 179.87 ± 2.19 nm and 0.06 ± 0.01, and 230.6 ± 9.10 nm and 0.17 ± 
0.01, respectively. 
 Encapsulation efficiency assays were performed for all siRNA formulations. The 
efficiencies are shown in Table 4 and the composition of the lipids and the flow rates at 
which there were produced can be found in the methods section . 
Formulation name 
RNA 
encapsulated 
(ng/uL) 
EE % 
Run 1 
siRNA:LNP 12.1 56 
siRNA:PEG-LNP 26 70 
Run 2 
siRNA:LNP 11.5 55 
siRNA:LNP_2 10.32 43 
siRNA:LNP-SS-OC 32.72 83 
siRNA:LNP_2-PEG 14.9 79 
siRNA:LNP-SS-OC-PEG 13.98 87 
The different formulations produced for different runs had varying amounts of 
encapsulated RNA and varying encapsulations efficiencies. The formulation with the 
highest total RNA encapsulated was siRNA:LNP-SS-OC (32.72 ng/uL) while the 
formulation with the highest encapsulation efficiency was siRNA:LNP-SS-OC-PEG (87 
%). 
CRISPR Formulations 
After producing siRNA loaded LNPs capable of knocking down GFP, 
formulations were adopted to produce particles for delivery of CRISPR gRNA and Cas9 
mRNA. The results of the particle size analysis and cell culture assays are shown in 
Figure 8. 
Table 4. Summary of encapsulation assays. The mass of encapsulated RNA is 
shown along with encapsulation efficiency for different formulations. 
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Figure 8. CRISPR formulation summary. LNPs were formulated in order to deliver 
RNA components of the CRISPR/Cas9 system. Cell viability (A) GFP fluorescence (B) 
were assayed to determine formulation efficacy. PDI (C) and particle size (D) of the 
particles was also evaluated. * p < 0.05, *** p = 0.0004, **** p < 0.0001. mRNA:msgrMAX 
refers to mRNA transfected with Lipofectamine MessengerMAX, a commercial 
transfection reagent. 
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Significant decreases in GFP expression were observed for several of the 
samples. Relative to the OptiMEM control and normalized to cell viability, 
gRNA:RNAiMAX had a GFP fluorescence of 79.97 ± 14.52 %, gRNA:RNAiMAX + 
mRNA:msgrMAX a fluorescence of 65.96 ± 8.49 %, gRNA:LNP + mRNA:LNP a 
fluorescence of 76.88 ± 8.88 %, gRNA:mRNA:LNP a fluorescence of 78.75 ± 9.39 %, and 
siRNA:LNP_2 a fluorescence of 62.93 ± 7.62. No significant changes in cell viability were 
noticed except for gRNA:RNAiMAX + mRNA:msgrMAX, which had  a small increase to 
108.90 ± 9.27. Particle sizes and PDI for gRNA:RNAiMAX, mRNA:LNP, 
gRNA:mRNA:LNP, and siRNA:LNP_2 were 111.90 ± 0.17 nm and 0.07 ± 0.00, 98.39 ± 
2.12 nm and 0.15 ± 0.01, 238.3 ± 23.6 nm and 0.09 ± 0.02, and 194.0 ± 1.0 nm and 0.08 
± 0.02, respectively. 
In order to assess the possibility of adapting this method of RNA-loaded LNP 
formulation and manufacturing, assessments were made to evaluate the sterility of the 
continuous processing system engineered in the Burgess Lab (Costa, Xu, Khan, & 
Burgess, 2016). To determine the possibility of contaminants, an RNase detection assay 
was performed. 
RNase detection in a complex processing stream 
Since RNA is very prone to degradation, it is important to take close care while 
exposing it to the processing flow required to make LNPs. In handling any form of RNA, 
it is critical to maintain a clean environment free of living or non-living contaminants (i.e. 
bacteria and RNases, respectively). With this in consideration, a preliminary experiment 
was conducted to assess the feasibility of adopting the formulations produced in this study 
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to the continuous processing system by performing an RNase detection assay. The 
results of this assay are presented in Figure 9. 
 
Figure 9. RNase detection assay. A shows all samples while B shows a close-up view 
of the four middle samples in A. Post-rinse indicates a system component which has 
been flushed with RNaseZAP® and ethanol. IDT (+) control consisting of RNase A, IDT 
(-) control consisting of RNase-free water. System injection consisting of water passed 
through the system, TFF indicates water passed through a tangential flow filtration 
apparatus not connected to the rest of the system. Finger contaminated sample was 
produced by putting a bare finger in water.  
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As expected, IDT (+) control consisting of RNase A showed significant RNase 
activity. Also as expected, the Finger contaminated sample also showed a high 
fluorescence. Prior to cleaning the system, RNase activity was detected, as shown in 
Figure 9B. However, after following the decontamination steps discussed in the methods, 
RNase activity was no longer detectable, when compared to IDT’s (-) control (RNase-free 
water). After rinsing with RNaseZAP® and ethanol, RNase activity was no longer detected 
by the assay, suggesting it is possible to clean the system and produce particles while 
maintaining RNA integrity. 
Discussion 
siRNA formulations 
In both runs, siRNA LNP formulations of the composition provided in Table 3 were 
effective in knocking down GFP in HEK293 cells. siRNA:LNP was similar in efficacy to 
RNAiMAX, a commercial transfection reagent optimized for these purposes. While similar 
in efficacy, siRNA:LNP formulations (Figure 6) and siRNA:LNP_2 formulations (Figure 7) 
are worth considering for pharmaceutical development, particularly because of the ability 
to control particle size and PDI by varying process conditions. Specifically, 
monodispersed particles of a controlled size were made via simple changes in flow rate 
conditions using the T-tube micromixer and syringe pumps.  In addition, at the lower flow 
condition of 1953 uL/min for the siRNA:LNP formulation, batch-to-batch variability was 
demonstrated between Run 1 and Run 2, suggesting that this particular formulation was 
not as consistent as siRNA:LNP_2, which had a particle size of about 200 nm with a PDI 
below 0.1 for both Run 1 and Run 2. It has been suggested that this inconsistency and 
overall instability is a result of the presence of cationic lipids in the particles (Ball, Bajaj, 
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& Whitehead, 2016). However, instability that demonstrates itself over time can be 
overcome by lyophilization of the products (Ball et al., 2016) . In addition, it was shown 
that for this plate-based transfection experiment, smaller particle size did not necessarily 
correlate with better knockdown efficacy since the maximum knockdown obtained with 
siRNA:LNP (Run 1) was 33.21 ± 4.84% of the control while that obtained for 
siRNA:LNP_2 (Run 2) was 61.69 ± 8.13 % of the control. In addition, incorporating SS-
OC did not appear to change knockdown efficacy when compared to similar formulations 
with no SS-OC present (Figure 7). It was expected that SS-OC would facilitate more 
significant knockdown as a result of its disulfide bond, which can be cleaved in the 
reducing intracellular environment. Cleavage of the disulfide bond turns SS-OC into a 
surfactant which can break apart the lipid and release RNA. However, a small mol % 
(2.7%) was used while formulating the particles and it is possible that more should be 
used to notice a change. Further studies incorporating a higher percentage of SS-OC 
should be conducted. No clear pattern was observed in RNA encapsulation assays, 
though it was noticed that higher encapsulation efficiencies for different formulations did 
not correlate with higher knockdowns. From a particle quality standpoint, formulations 
with PEG incorporated did not register any significant knockdown in GFP expression. 
However, in vitro efficacy may not directly correlate with in vivo efficacy, so formulations 
which were not effective in this study may be effective in an in vivo model (Chen et al., 
2012). It is also important to note that incorporating PEG into LNPs gives “stealth” 
properties, extending blood-circulation times and limiting detection by the immune system  
(Immordino, Dosio, & Cattel, 2006).  
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CRISPR Formulations 
The LNP delivery of CRISPR gRNA and Cas9 mRNA in this study demonstrates 
that LNPs may be a suitable vehicle for the CRISPR/Cas9 system. The positive control 
transfected with gRNA:RNAiMAX and mRNA:msgrMAX showed significant knockdown 
(p < 0.0001). Significant knockdown was noticed for CRISPR formulations, though it was 
also noticed for samples transfected solely with gRNA:LNP. While this was expected to 
serve as a negative control with no significant knockdown when compared to the 
OptiMEM control, GFP expression appeared to decrease. Though it is neither 
demonstrated in this study or in the literature, interaction between complementary bases 
of the crRNA and GFP mRNA may have inhibited its expression. RNA binding assays 
between crRNA and corresponding mRNA could be performed to test this prediction. 
Particles of small size and PDI were successfully formulated with CRISPR RNA. 
gRNA:LNP had a particle size of ~111.90 nm and a PDI of 0.07. mRNA:LNP particles 
appeared to have a particle size of ~98.39 nm and a PDI of 0.15. The formulation in which 
both gRNA and mRNA were delivered in the same particle, gRNA:mRNA:LNP, had a 
particle size of 238.3 nm and a PDI of 0.09. Achieving particles with these qualities was 
empirically driven and in order to more fully understand their formation characteristics, 
the particles should instead be produced by incrementally changing flow rates, lipid ratios, 
lipid concentration and RNA concentration. In addition, in order to independently establish 
the efficacy of the mRNA:LNP formulation, a western blot against the Cas9 protein should 
be performed for all samples transfected in the study. To assess the efficacy of the 
gRNA/Cas9 complex, a cleavage detection assay can also be performed. In order to 
compare the transient or steady effect of the change in GFP expression, the cells may 
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also be passaged and monitored for GFP expression over time.  Nonetheless, it has been 
established that producing low size, low PDI LNPs with CRISPR RNAs is possible with a 
T-tube micromixer.  Further investigation is required to determine if regulating genes with 
RNA therapeutics and CRISPR technology can be made possible with LNPs produced in 
a similar fashion to this study. 
RNase Detection in A Complex Processing Stream 
Precise control of processing conditions can be achieved by implementing 
continuous processing and process analytical technology (PAT). In order to take 
advantage of these advances in pharmaceutical technology, it is necessary to understand 
whether or not the formulations can be produced with a complex processing stream. 
Figure 9 demonstrates the possibility of adapting RNA formulations to the continuous 
processing system in the Burgess Lab (Costa et al., 2016). Accordingly, the studied flow 
conditions for forming LNPs with RNAse could be further investigated using this larger-
scale system; however, a larger quantity of RNA would be required. Moreover, as 
demonstrated in Figure 9, the system can be easily decontaminated of nucleases, which 
is extremely important to preserve the RNA integrity of the formulation. In order to ensure 
the quality of the particles, it would be necessary to incorporate this assay into a standard 
operating procedure prior to processing and as a quality control measure.  
Future Directions 
Optimization of Formulations 
Though significant knockdown was observed for siRNA and CRISPR formulations, 
further optimization is required to maximize knockdown and knockout. Adjusting lipid 
ratio, lipid concentration, and flow rates can have an effect on particle size and 
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encapsulation efficiency, product qualities which are important from a quality control and 
material cost perspective. In order to more thoroughly understand the formation of 
particles under these variable conditions, a design-of-experiments DoE approach can be 
taken to decide on these variable conditions and find optimal parameters to produce 
potent and highly controlled particles.  
Stability Testing 
Though formulations appeared to be stable at room temperature for at least a day, 
more thorough investigations are required to assess the feasibility for further 
pharmaceutical development. Stability testing can be conducted by producing the same 
formulations used in this study and testing them for aggregation periodically through DLS. 
In addition, experiments can be conducted to periodically evaluate encapsulation 
efficiency to ensure that RNA is not undergoing degradation within the particles. It is 
possible that combinations of the various lipids used to produce the LNPs can influence 
their stability and product quality. 
Continuous processing of LNPs 
As a method of producing drug products, continuous processing offers significant 
advantages over traditional batch manufacturing methods. In a continuous processing 
system, a drug product is created in a highly controlled manner from start to finish without 
exposure to the external environment. This allows application of continuous flow 
techniques which can be amended to produce high volumes of active pharmaceutical 
ingredients (APIs) or end products. It also allows for tighter regulation of processing 
conditions, such as a temperature, pressure, and concentration. Furthermore, 
incorporation of PAT provides real-time information on product quality. Automated 
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feedback mechanisms incorporated into PAT can allow users to set parameters which 
are evaluated by quality control guidelines (Burcham, Florence, & Johnson, 2018).  
Amending the formulations for continuous processing would therefore prove valuable 
from a quality-control and manufacturing viewpoint. The RNase detection assay shown 
in Figure 9 highlights the plausibility of adopting the formulations to the continuous 
processing system located in the Burgess Lab without risking RNA degradation. 
Conclusions 
The siRNA:LNP formulations produced in this study were successful in knocking 
down GFP in HEK293 cells. These formulations had significant GFP knockdown, low 
cytotoxicity and could be empirically formulated to produce particles of low size and PDI. 
CRISPR gRNA, mRNA, and gRNA+mRNA were formulated to produce LNPs low in 
particle size and PDI. LNP delivery of CRISPR gRNA and Cas9 mRNA to target GFP in 
HEK293 cells demonstrates that LNPs may be a suitable vehicle for the CRISPR/Cas9 
system, though more investigation is required. LNP lipid composition is critical to nucleic 
acid delivery. Factors which influence LNP size, PDI, and encapsulation efficiency are 
critical for pharmaceutical development though they do not directly correlate with in vitro 
efficacy, as demonstrated in this study. 
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